Vaccinex EBITDA

What does Vaccinex do? Vaccinex, Inc. develops targeted biotherapeutics for serious diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The company generates revenue through its SEMA4D antibody platform, focusing on VX15 for non-small cell lung cancer, osteosarcoma, melanoma, and Huntington’s disease. It also utilizes the ActiveMAb antibody discovery platform for developing VX5, which is in preclinical stages for multiple sclerosis and other autoimmune disorders. Vaccinex targets healthcare providers and pharmaceutical companies seeking novel treatments for unmet medical needs. Vaccinex's lead product candidate VX15 is developed using the SEMA4D platform to address non-small cell lung cancer, osteosarcoma, and melanoma. The company's ActiveMAb platform supports the creation of high-affinity human monoclonal antibodies, which are used in VX5 for multiple sclerosis treatment. These platforms enable Vaccinex to offer innovative solutions for diseases with limited therapeutic options. The company's focus on clinical-stage development means it currently does not generate revenue from product sales but relies on partnerships and potential future licensing agreements. Vaccinex's target segments include patients with non-small cell lung cancer, osteosarcoma, melanoma, Huntington’s disease, and multiple sclerosis, as well as pharmaceutical companies interested in acquiring or co-developing its platforms and product candidates. Vaccinex is one of the most popular companies on Eulerpool.